Drug intelligence / Profile preview

HRS-7085

Development stage: Phase 2
Lead developer: Jiangsu Hengrui Medicine
Modality: Small Molecules
Administration: Oral

Overview

HRS-7085 is an orally administered small molecule drug in tablet formulation under development for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The drug is currently in Phase I clinical trials, with studies evaluating its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers. The precise mechanism of action for HRS-7085 has not been disclosed or defined publicly. Development efforts have been reported by both Jiangsu Hengrui Medicine and Atridia[1][2][3][4][8].

Other names: HRS 7085HRS7085HRS-7085

Targets

RORC (Retinoic acid receptor-related orphan receptor gamma)

Beyond the preview

Go deeper on HRS-7085.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-7085.

Explore the full profile